Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 121 | 198 | 98 | 76 | 114 |
| Gross Profit | 121 | 198 | 98 | 76 | 114 |
| Operating Expenses | 13,212 | 10,594 | 7,478 | 6,907 | 6,348 |
| Operating Income | -13,091 | -10,396 | -7,380 | -6,831 | -6,234 |
| Other Income | 934 | 1,001 | 1,139 | 680 | 163 |
| Pre-tax Income | -12,157 | -9,395 | -6,241 | -6,151 | -6,071 |
| Net Income Continuous | -12,157 | -9,395 | -6,241 | -6,151 | -6,071 |
| Net Income Discontinuous | 0 | -11 | -8 | -37 | -513 |
| Net Income | $-12,157 | $-9,406 | $-6,249 | $-6,188 | $-6,584 |
| EPS Basic Total Ops | -0.29 | -0.22 | -0.15 | 4.06 | -2.01 |
| EPS Basic Continuous Ops | -0.29 | -0.22 | -0.15 | 3.95 | -1.85 |
| EPS Basic Discontinuous Ops | N/A | 0.00 | 0.00 | 0.11 | -0.16 |
| EPS Diluted Total Ops | -0.29 | -0.22 | -0.15 | 4.06 | -2.01 |
| EPS Diluted Continuous Ops | -0.29 | -0.22 | -0.15 | 3.95 | -1.85 |
| EPS Diluted Discontinuous Ops | N/A | 0.00 | 0.00 | 0.11 | -0.16 |
| EPS Diluted Before Non-Recurring Items | -0.29 | -0.22 | -0.15 | N/A | N/A |
| EBITDA(a) | $-13,597 | $-11,012 | $-8,157 | $-6,831 | $-6,234 |